Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs)

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 212-220

  Irandoust, Mahban ^a   van den Berg, Timo K ^b   Kaspers, Gertjan J L ^a   Cloos, Jacqueline ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

Phosphatase inhibitor; Protein tyrosine phosphatase; SHP 1; SHP 2; SIRP

Indexed keywords

CD47 ANTIGEN; JANUS KINASE; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SIGNAL REGULATORY PROTEIN ALPHA; STAT PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PROTEIN TYROSINE PHOSPHATASE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHROMOSOME 12P; CHROMOSOME 20P; DOWN REGULATION; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NEOPLASM; SRC HOMOLOGY DOMAIN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; SRC HOMOLOGY DOMAINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64049083563     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787313864     Document Type: Review

References (119)

1. Hunter, T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect., 1998, 94, 81-119.
2. Zhang, Z.Y. Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol., 2001, 5(4), 416-423.
3. Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. Cell, 2004, 117(6), 699-711.
4. Andersen, J.N.; Mortensen, O.H.; Peters, G.H.; Drake, P.G.; Iversen, L.F.; Olsen, O.H.; Jansen, P.G.; Andersen, H.S.; Tonks, N.K.; Moller, N.P. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell Biol., 2001, 21(21), 7117-7136.
5. Tiganis, T.; Bennett, A.M. Protein tyrosine phosphatase function: the substrate perspective. Biochem. J., 2007, 402(1), 1-15.
6. Zhang, Z.Y. Mechanistic studies on protein tyrosine phosphatases. Prog. Nucleic Acid Res. Mol. Biol., 2003, 73, 171-220.
7. Zhang, Z.Y. Functional studies of protein tyrosine phosphatases with chemical approaches. Biochim. Biophys. Acta, 2005, 1754(1-2), 100-107.
8. Alessi, D.R.; Gomez, N.; Moorhead, G.; Lewis, T.; Keyse, S.M.; Cohen, P. Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell lines. Curr. Biol., 1995, 5(3), 283-295.
9. Johnson, L.N.; Noble, M.E.; Owen, D.J. Active and inactive protein kinases: structural basis for regulation. Cell, 1996, 85(2), 149-158.
10. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B.E.; Karandikar, M.; Berman, K.; Cobb, M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev., 2001, 22(2), 153-183.
11. Pulido, R.; Zuniga, A.; Ullrich, A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J., 1998, 17(24), 7337-7350.
12. Burridge, K.; Sastry, S.K.; Sallee, J.L. Regulation of cell adhesion by protein-tyrosine phosphatases. I. Cell-matrix adhesion. J. Biol. Chem., 2006, 281(23), 15593-15596.
13. Huynh, H.; Bottini, N.; Williams, S.; Cherepanov, V.; Musumeci, L.; Saito, K.; Bruckner, S.; Vachon, E.; Wang, X.; Kruger, J.; Chow, C.W.; Pellecchia, M.; Monosov, E.; Greer, P.A.; Trimble, W.; Downey, G.P.; Mustelin, T. Control of vesicle fusion by a tyrosine phosphatase. Nat. Cell Biol., 2004, 6(9), 831-839.
14. Ibarra-Sanchez, M.J.; Simoncic, P.D.; Nestel, F.R.; Duplay, P.; Lapp, W.S.; Tremblay, M.L. The T-cell protein tyrosine phosphatase. Semin. Immunol., 2000, 12(4), 379-386.
15. Sallee, J.L.; Wittchen, E.S.; Burridge, K. Regulation of cell adhesion by protein-tyrosine phosphatases: II. Cell-cell adhesion. J. Biol. Chem., 2006, 281(24), 16189-16192.
16. Tiganis, T.; Bennett, A.M.; Ravichandran, K.S.; Tonks, N.K. Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol. Cell Biol., 1998, 18(3), 1622-1634.
17. Tonks, N.K. PTP1B: from the sidelines to the front lines! FEBS Lett., 2003, 546(1), 140-148.
18. Imhof, D.; Wavreille, A.S.; May, A.; Zacharias, M.; Tridandapani, S.; Pei, D. Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains. Critical roles of residues beyond the pY+3 position. J. Biol. Chem., 2006, 281(29), 20271-20282.
19. Wavreille, A.S.; Garaud, M.; Zhang, Y.; Pei, D. Defining SH2 domain and PTP specificity by screening combinatorial peptide libraries. Methods, 2007, 42(3), 207-219.
20. Wang, N.; Li, Z.; Ding, R.; Frank, G.D.; Senbonmatsu, T.; Landon, E.J.; Inagami, T.; Zhao, Z.J. Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J. Biol. Chem., 2006, 281(31), 21878-21883.
21. Byth, K.F.; Conroy, L.A.; Howlett, S.; Smith, A.J.; May, J.; Alexander, D.R.; Holmes, N. CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. J. Exp. Med., 1996, 183(4), 1707-1718.
22. Bliska, J.B.; Guan, K.L.; Dixon, J.E.; Falkow, S. Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc. Natl. Acad. Sci. USA, 1991, 88(4), 1187-1191.
23. Koul, A.; Choidas, A.; Treder, M.; Tyagi, A.K.; Drlica, K.; Singh, Y.; Ullrich, A. Cloning and characterization of secretory tyrosine phosphatases of Mycobacterium tuberculosis. J. Bacteriol., 2000, 182(19), 5425-5432.
24. Schmidt, A.; Rutledge, S.J.; Endo, N.; Opas, E.E.; Tanaka, H.; Wesolowski, G.; Leu, C.T.; Huang, Z.; Ramachandaran, C.; Rodan, S.B.; Rodan, G.A. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. USA, 1996, 93(7), 3068-3073.
25. Buckley, D.A.; Cheng, A.; Kiely, P.A.; Tremblay, M.L.; O'Connor, R. Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts. Mol. Cell Biol., 2002, 22(7), 1998-2010.
26. Tonks, N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol., 2006, 7(11), 833-846.
27. Ostman, A.; Hellberg, C.; Bohmer, F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer, 2006, 6(4), 307-320.
28. Wang, Z.; Shen, D.; Parsons, D.W.; Bardelli, A.; Sager, J.; Szabo, S.; Ptak, J.; Silliman, N.; Peters, B.A.; van der Heijden, M.S.; Parmigiani, G.; Yan, H.; Wang, T.L.; Riggins, G.; Powell, S.M.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 2004, 304(5674), 1164-1166.
29. Bentires-Alj, M.; Paez, J.G.; David, F.S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J.M.; Richardson, A.; Bardelli, A.; Sugarbaker, D.J.; Richards, W.G.; Du, J.; Girard, L.; Minna, J.D.; Loh, M.L.; Fisher, D.E.; Velculescu, V.E.; Vogelstein, B.; Meyerson, M.; Sellers, W.R.; Neel, B.G. Activating mutations of the noonan syndrome-associated SHP2/ PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res., 2004, 64(24), 8816-8820.
30. Tartaglia, M.; Niemeyer, C.M.; Fragale, A.; Song, X.; Buechner, J.; Jung, A.; Hahlen, K.; Hasle, H.; Licht, J.D.; Gelb, B.D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet., 2003, 34(2), 148-150.
31. Martinelli, S.; Carta, C.; Flex, E.; Binni, F.; Cordisco, E.L.; Moretti, S.; Puxeddu, E.; Tonacchera, M.; Pinchera, A.; McDowell, H.P.; Dominici, C.; Rosolen, A.; Di Rocco, C.; Riccardi, R.; Celli, P.; Picardo, M.; Genuardi, M.; Grammatico, P.; Sorcini, M.; Tartaglia, M. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet. Cytogenet., 2006, 166(2), 124-129.
32. Loh, M.L.; Vattikuti, S.; Schubbert, S.; Reynolds, M.G.; Carlson, E.; Lieuw, K.H.; Cheng, J.W.; Lee, C.M.; Stokoe, D.; Bonifas, J.M.; Curtiss, N.P.; Gotlib, J.; Meshinchi, S.; Le Beau, M.M.; Emanuel, P.D.; Shannon, K.M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 2004, 103(6), 2325-2331.
33. Amin, H.M.; Hoshino, K.; Yang, H.; Lin, Q.; Lai, R.; Garcia-Manero, G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J. Pathol., 2007, 212(4), 402-410.
34. Bruecher-Encke, B.; Griffin, J.D.; Neel, B.G.; Lorenz, U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia, 2001, 15(9), 1424-1432.
35. Oka, T.; Ouchida, M.; Koyama, M.; Ogama, Y.; Takada, S.; Nakatani, Y.; Tanaka, T.; Yoshino, T.; Hayashi, K.; Ohara, N.; Kondo, E.; Takahashi, K.; Tsuchiyama, J.; Tanimoto, M.; Shimizu, K.; Akagi, T. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res., 2002, 62(22), 6390-6394.
36. Kharitonenkov, A.; Chen, Z.; Sures, I.; Wang, H.; Schilling, J.; Ullrich, A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature, 1997, 386(6621), 181-186.
37. Pei, D.; Lorenz, U.; Klingmuller, U.; Neel, B.G.; Walsh, C.T. Intramolecular regulation of protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains. Biochemistry, 1994, 33(51), 15483-15493.
38. Pluskey, S.; Wandless, T.J.; Walsh, C.T.; Shoelson, S.E. Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J. Biol. Chem., 1995, 270(7), 2897-2900.
39. Liu, Y.; Kruhlak, M.J.; Hao, J.J.; Shaw, S. Rapid T cell receptor-mediated SHP-1 S591 phosphorylation regulates SHP-1 cellular localization and phosphatase activity. J. Leukoc. Biol., 2007, 82(3), 742-751.
40. Poole, A.W.; Jones, M.L. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal., 2005, 17(11), 1323-1332.
41. Neel, B.G.; Gu, H.; Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci., 2003, 28(6), 284-293.
42. Kozlowski, M.; Mlinaric-Rascan, I.; Feng, G.S.; Shen, R.; Pawson, T.; Siminovitch, K.A. Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J. Exp. Med., 1993, 178(6), 2157-2163.
43. Mena-Duran, A.V.; Togo, S.H.; Bazhenova, L.; Cervera, J.; Bethel, K.; Senent, M.L.; Nieva, J.; Sanz, G.F.; Sanz, M.A.; Saven, A.; Mustelin, T. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br. J. Haematol., 2005, 129(6), 791-794.
44. Koyama, M.; Oka, T.; Ouchida, M.; Nakatani, Y.; Nishiuchi, R.; Yoshino, T.; Hayashi, K.; Akagi, T.; Seino, Y. Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab. Invest., 2003, 83(12), 1849-1858.
45. Witkiewicz, A.; Raghunath, P.; Wasik, A.; Junkins-Hopkins, J.M.; Jones, D.; Zhang, Q.; Odum, N.; Wasik, M.A. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum. Pathol., 2007, 38(3), 462-467.
46. Chim, C.S.; Fung, T.K.; Cheung, W.C.; Liang, R.; Kwong, Y.L. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 2004, 103(12), 4630-4635.
47. Chim, C.S.; Wong, K.Y.; Loong, F.; Srivastava, G. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia, 2004, 18(2), 356-358.
48. Simoneau, M.; Boulanger, J.; Coulombe, G.; Renaud, M.A.; Duchesne, C.; Rivard, N. Activation of Cdk2 stimulates proteasome-dependent truncation of tyrosine phosphatase SHP-1 in human proliferating intestinal epithelial cells. J. Biol. Chem., 2008, 283(37), 25544-25556.
49. Valentino, L.; Pierre, J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol., 2006, 71(6), 713-721.
50. Wu, C.; Guan, Q.; Wang, Y.; Zhao, Z.J.; Zhou, G.W. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J. Cell Biochem., 2003, 90(5), 1026-1037.
51. Wu, C.; Sun, M.; Liu, L.; Zhou, G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene, 2003, 306, 1-12.
52. Zapata, P.D.; Ropero, R.M.; Valencia, A.M.; Buscail, L.; Lopez, J.I.; Martin-Orozco, R.M.; Prieto, J.C.; Angulo, J.; Susini, C.; Lopez-Ruiz, P.; Colas, B. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J. Clin. Endocrinol. Metab., 2002, 87(2), 915-926.
53. Mok, S.C.; Kwok, T.T.; Berkowitz, R.S.; Barrett, A.J.; Tsui, F.W. Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer. Gynecol. Oncol., 1995, 57(3), 299-303.
54. Yip, S.S.; Crew, A.J.; Gee, J.M.; Hui, R.; Blamey, R.W.; Robertson, J.F.; Nicholson, R.I.; Sutherland, R.L.; Daly, R.J. Upregulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int. J. Cancer, 2000, 88(3), 363-368.
55. Hof, P.; Pluskey, S.; Dhe-Paganon, S.; Eck, M.J.; Shoelson, S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell, 1998, 92(4), 441-450.
56. Barford, D.; Neel, B.G. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure, 1998, 6(3), 249-254.
57. Cunnick, J.M.; Meng, S.; Ren, Y.; Desponts, C.; Wang, H.G.; Djeu, J.Y.; Wu, J. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J. Biol. Chem., 2002, 277(11), 9498-9504.
58. Chan, G.; Kalaitzidis, D.; Neel, B.G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev., 2008, 27(2), 179-192.
59. Mohi, M.G.; Williams, I.R.; Dearolf, C.R.; Chan, G.; Kutok, J.L.; Cohen, S.; Morgan, K.; Boulton, C.; Shigematsu, H.; Keilhack, H.; Akashi, K.; Gilliland, D.G.; Neel, B.G. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell, 2005, 7(2), 179-191.
60. Goemans, B.F.; Zwaan, C.M.; Martinelli, S.; Harrell, P.; de Lange, D.; Carta, C.; Reinhardt, D.; Hahlen, K.; Creutzig, U.; Tartaglia, M.; Heinrich, M.C.; Kaspers, G.J. Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. Br. J. Haematol., 2005, 130(5), 801-803.
61. Tartaglia, M.; Martinelli, S.; Iavarone, I.; Cazzaniga, G.; Spinelli, M.; Giarin, E.; Petrangeli, V.; Carta, C.; Masetti, R.; Arico, M.; Locatelli, F.; Basso, G.; Sorcini, M.; Pession, A.; Biondi, A. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br. J. Haematol., 2005, 129(3), 333-339.
62. Loh, M.L.; Reynolds, M.G.; Vattikuti, S.; Gerbing, R.B.; Alonzo, T.A.; Carlson, E.; Cheng, J.W.; Lee, C.M.; Lange, B.J.; Meshinchi, S. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia, 2004, 18(11), 1831-1834.
63. Hatakeyama, M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer, 2004, 4(9), 688-694.
64. Agazie, Y.M.; Hayman, M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell Biol., 2003, 23(21), 7875-7886.
65. Burks, J.; Agazie, Y.M. Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. Oncogene, 2006, 25(54), 7166-7179.
66. Scherr, M.; Chaturvedi, A.; Battmer, K.; Dallmann, I.; Schultheis, B.; Ganser, A.; Eder, M. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood, 2006, 107(8), 3279-3287.
67. Xu, D.; Qu, C.K. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci., 2008, 13, 4925-4932.
68. Barclay, A.N.; Brown, M.H. The SIRP family of receptors and immune regulation. Nat. Rev. Immunol., 2006, 6(6), 457-464.
69. van Beek, E.M.; Cochrane, F.; Barclay, A.N.; van den Berg, T.K. Signal regulatory proteins in the immune system. J. Immunol., 2005, 175(12), 7781-7787.
70. Wang, H.; Madariaga, M.L.; Wang, S.; Van Rooijen, N.; Oldenborg, P.A.; Yang, Y.G. Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells. Proc. Natl. Acad. Sci. USA, 2007, 104(34), 13744-13749.
71. Ishikawa-Sekigami, T.; Kaneko, Y.; Saito, Y.; Murata, Y.; Okazawa, H.; Ohnishi, H.; Oldenborg, P.A.; Nojima, Y.; Matozaki, T. Enhanced phagocytosis of CD47-deficient red blood cells by splenic macrophages requires SHPS-1. Biochem. Biophys. Res. Commun., 2006, 343(4), 1197-1200.
72. Okazawa, H.; Motegi, S.; Ohyama, N.; Ohnishi, H.; Tomizawa, T.; Kaneko, Y.; Oldenborg, P.A.; Ishikawa, O.; Matozaki, T. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J. Immunol., 2005, 174(4), 2004-2011.
73. Takenaka, K.; Prasolava, T.K.; Wang, J.C.; Mortin-Toth, S.M.; Khalouei, S.; Gan, O.I.; Dick, J.E.; Danska, J.S. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat. Immunol., 2007, 8(12), 1313-1323.
74. van den Berg, T.K.; van der Schoot, C.E. Innate immune 'self' recognition: a role for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation. Trends Immunol., 2008, 29(5), 203-206.
75. Seiffert, M.; Cant, C.; Chen, Z.; Rappold, I.; Brugger, W.; Kanz, L.; Brown, E.J.; Ullrich, A.; Buhring, H.J. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counter-receptor CD47. Blood, 1999, 94(11), 3633-3643.
76. Koshimizu, H.; Araki, T.; Takai, S.; Yokomaku, D.; Ishikawa, Y.; Kubota, M.; Sano, S.; Hatanaka, H.; Yamada, M. Expression of CD47/ integrin-associated protein induces death of cultured cerebral cortical neurons. J. Neurochem., 2002, 82(2), 249-257.
77. Kaspers, G.J.; Zwaan, C.M. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica, 2007, 92(11), 1519-1532.
78. Soverini, S.; Martinelli, G.; Iacobucci, I.; Baccarani, M. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev. Anticancer Ther., 2008, 8(6), 853-864.
79. Pratz, K.; Levis, M. Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk. Lymphoma, 2008, 49(5), 852-863.
80. Sarmiento, R.; Bonginelli, P.; Cacciamani, F.; Salerno, F.; Gasparini, G. Gastrointestinal stromal tumors (GISTs): from science to targeted therapy. Int. J. Biol. Markers, 2008, 23(2), 96-110.
81. Ren, H.; Yang, B.F.; Rainov, N.G. Receptor tyrosine kinases as therapeutic targets in malignant glioma. Rev. Recent Clin. Trials, 2007, 2(2), 87-101.
82. Ng, R.; Chen, E.X. Sorafenib (BAY 43-9006): review of clinical development. Curr. Clin. Pharmacol., 2006, 1(3), 223-228.
83. Nahleh, Z.A. Molecularly targeted therapy in breast cancer: the new generation. Recent Patents Anticancer Drug Discov., 2008, 3(2), 100-104.
84. Yasui, H.; Imai, K. Novel molecular-targeted therapeutics for the treatment of cancer. Anticancer Agents Med. Chem., 2008, 8(5), 470-480.
85. Zhang, Z.Y.; Lee, S.Y. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin. Investig. Drugs, 2003, 12(2), 223-233.
86. Flint, A.J.; Tiganis, T.; Barford, D.; Tonks, N.K. Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc. Natl. Acad. Sci. USA, 1997, 94(5), 1680-1685.
87. Liu, F.; Chernoff, J. Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor. Biochem. J., 1997, 327. (Pt. 1), 139-145.
88. Johnson, T.O.; Ermolieff, J.; Jirousek, M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov., 2002, 1(9), 696-709.
89. McCain, D.F.; Wu, L.; Nickel, P.; Kassack, M.U.; Kreimeyer, A.; Gagliardi, A.; Collins, D.C.; Zhang, Z.Y. Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases. J. Biol. Chem., 2004, 279(15), 14713-14725.
90. Alvi, K.A.; Casey, A.; Nair, B.G. Pulchellalactam: a CD45 protein tyrosine phosphatase inhibitor from the marine fungus Corollospora pulchella. J. Antibiot. (Tokyo), 1998, 51(5), 515-517.
91. Urbanek, R.A.; Suchard, S.J.; Steelman, G.B.; Knappenberger, K.S.; Sygowski, L.A.; Veale, C.A.; Chapdelaine, M.J. Potent reversible inhibitors of the protein tyrosine phosphatase CD45. J. Med. Chem., 2001, 44(11), 1777-1793.
92. Hamaguchi, T.; Takahashi, A.; Manaka, A.; Sato, M.; Osada, H. TU-572, a potent and selective CD45 inhibitor, suppresses IgE-mediated anaphylaxis and murine contact hypersensitivity reactions. Int. Arch. Allergy Immunol., 2001, 126(4), 318-324.
93. Pathak, M.K.; Yi, T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol., 2001, 167(6), 3391-3397.
94. Arabaci, G.; Yi, T.; Fu, H.; Porter, M.E.; Beebe, K.D.; Pei, D. alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship. Bioorg. Med. Chem. Lett., 2002, 12(21), 3047-3050.
95. Hellmuth, K.; Grosskopf, S.; Lum, C.T.; Wurtele, M.; Roder, N.; von Kries, J.P.; Rosario, M.; Rademann, J.; Birchmeier, W. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl. Acad. Sci. USA, 2008, 105(20), 7275-7280.
96. Chen, L.; Sung, S.S.; Yip, M.L.; Lawrence, H.R.; Ren, Y.; Guida, W.C.; Sebti, S.M.; Lawrence, N.J.; Wu, J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol., 2006, 70(2), 562-570.
97. Shen, K.; Keng, Y.F.; Wu, L.; Guo, X.L.; Lawrence, D.S.; Zhang, Z.Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J. Biol. Chem., 2001, 276(50), 47311-47319.
98. Noren-Muller, A.; Reis-Correa, I., Jr.; Prinz, H.; Rosenbaum, C.; Saxena, K.; Schwalbe, H.J.; Vestweber, D.; Cagna, G.; Schunk, S.; Schwarz, O.; Schiewe, H.; Waldmann, H. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl. Acad. Sci. USA, 2006, 103(28), 10606-10611.
99. Lawrence, H.R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S.S.; Szymanski, A.M.; Yip, M.L.; Guida, W.C.; Sebti, S.M.; Wu, J.; Lawrence, N.J. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J. Med. Chem., 2008, 51(16), 4948-4956.
100. Cazales, M.; Boutros, R.; Brezak, M.C.; Chaumeron, S.; Prevost, G.; Ducommun, B. Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly. Mol. Cancer Ther., 2007, 6(1), 318-325.
101. Brezak, M.C.; Quaranta, M.; Contour-Galcera, M.O.; Lavergne, O.; Mondesert, O.; Auvray, P.; Kasprzyk, P.G.; Prevost, G.P.; Ducommun, B. Inhibition of human tumor cell growth in. vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol. Cancer Ther., 2005, 4(9), 1378-1387.
102. Blanchard, J.L.; Epstein, D.M.; Boisclair, M.D.; Rudolph, J.; Pal, K. Dysidiolide and related gamma-hydroxy butenolide compounds as inhibitors of the protein tyrosine phosphatase, CDC25. Bioorg. Med. Chem. Lett., 1999, 9(17), 2537-2538.
103. Horiguchi, T.; Nishi, K.; Hakoda, S.; Tanida, S.; Nagata, A.; Okayama, H. Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochem. Pharmacol., 1994, 48(11), 2139-2141.
104. Loukaci, A.; Le Saout, I.; Samadi, M.; Leclerc, S.; Damiens, E.; Meijer, L.; Debitus, C.; Guyot, M. Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. Bioorg. Med. Chem., 2001, 9(11), 3049-3054.
105. Kar, S.; Wang, M.; Ham, S.W.; Carr, B.I. H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK. Cancer Biol. Ther., 2006, 5(10), 1340-1347.
106. Ling, Q.; Huang, Y.; Zhou, Y.; Cai, Z.; Xiong, B.; Zhang, Y.; Ma, L.; Wang, X.; Li, X.; Li, J.; Shen, J. Illudalic acid as a potential LAR inhibitor: synthesis, SAR, and preliminary studies on the mechanism of action. Bioorg. Med. Chem., 2008, 16(15), 7399-7409.
107. Pathak, M.K.; Dhawan, D.; Lindner, D.J.; Borden, E.C.; Farver, C.; Yi, T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol. Cancer Ther., 2002, 1(14), 1255-1264.
108. Ahn, J.H.; Kim, S.J.; Park, W.S.; Cho, S.Y.; Ha, J.D.; Kim, S.S.; Kang, S.K.; Jeong, D.G.; Jung, S.K.; Lee, S.H.; Kim, H.M.; Park, S.K.; Lee, K.H.; Lee, C.W.; Ryu, S.E.; Choi, J.K. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(11), 2996-2999.
109. Choi, S.K.; Oh, H.M.; Lee, S.K.; Jeong, D.G.; Ryu, S.E.; Son, K.H.; Han, D.C.; Sung, N.D.; Baek, N.I.; Kwon, B.M. Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3). Nat. Prod. Res., 2006, 20(4), 341-346.
110. Liang, L.; Lim, K.L.; Seow, K.T.; Ng, C.H.; Pallen, C.J. Calmodulin binds to and inhibits the activity of the membrane distal catalytic domain of receptor protein-tyrosine phosphatase alpha. J. Biol. Chem., 2000, 275(39), 30075-30081.
111. Liang, F.; Kumar, S.; Zhang, Z.Y. Proteomic approaches to studying protein tyrosine phosphatases. Mol. Biosyst., 2007, 3(5), 308-316.
112. Tautz, L.; Mustelin, T. Strategies for developing protein tyrosine phosphatase inhibitors. Methods, 2007, 42(3), 250-260.
113. Hampel, K.; Kaufhold, I.; Zacharias, M.; Bohmer, F.D.; Imhof, D. Phosphopeptide ligands of the SHP-1 N-SH2 domain: effects on binding and stimulation of phosphatase activity. ChemMedChem., 2006, 1(8), 869-877.
114. Wlodarski, P.; Zhang, Q.; Liu, X.; Kasprzycka, M.; Marzec, M.; Wasik, M.A. PU.1 activates transcription of SHP-1 gene in hematopoietic cells. J. Biol. Chem., 2007, 282(9), 6316-6323.
115. Zhang, L.; Cheng, X.; Li, Y.; Poh, C.; Zeng, T.; Priddy, R.; Lovas, J.; Freedman, P.; Daley, T.; Rosin, M.P. High frequency of allelic loss in dysplastic lichenoid lesions. Lab. Invest., 2000, 80(2), 233-237.
116. Adams, S.; van der Laan, L.J.; Vernon-Wilson, E.; Renardel de Lavalette, C.; Dopp, E.A.; Dijkstra, C.D.; Simmons, D.L.; van den Berg, T.K. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J. Immunol., 1998, 161(4), 1853-1859.
117. Krejci, P.; Masri, B.; Salazar, L.; Farrington-Rock, C.; Prats, H.; Thompson, L.M.; Wilcox, W.R. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J. Biol. Chem., 2007, 282(5), 2929-2936.
118. Shankar, S.; Srivastava, R.K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv. Exp. Med. Biol., 2008, 615, 261-298.
119. Stommel, J.M.; Kimmelman, A.C.; Ying, H.; Nabioullin, R.; Ponugoti, A.H.; Wiedemeyer, R.; Stegh, A.H.; Bradner, J.E.; Ligon, K.L.; Brennan, C.; Chin, L.; DePinho, R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318(5848), 287-290.